Last Updated on April 21, 2026
The short answer: naltrexone and GLP-1 drugs like Ozempic both reduce the urge to drink — but they work through different mechanisms, carry different evidence bases, and come at very different price points. Naltrexone is FDA-approved for alcohol use disorder, widely available, and has decades of clinical trials behind it. GLP-1 medications are newer, prescribed off-label for drinking, and not yet covered by insurance for that use. If your primary goal is drinking less, naltrexone is currently the stronger, more accessible choice, though GLP-1 research is moving fast.
You’ve probably seen the headlines: people on Ozempic quietly mentioning they’ve lost the desire to drink. Maybe you’ve wondered whether that drug, or something like it, could help you cut back. Or maybe you’ve heard about naltrexone and wondered how it compares. Both are real options. Both do something meaningful in the brain. But they’re not the same thing, and understanding the difference could save you time, money, and confusion.
How Naltrexone Works to Help You Drink Less
Naltrexone has been FDA-approved for alcohol use disorder since 1994, giving it a clinical track record few alcohol moderation medications can match. It works by blocking opioid receptors in the brain, which are part of the pathway that makes alcohol feel rewarding. When those receptors are blocked, the dopamine surge that typically follows a drink is significantly blunted. Alcohol still enters your system, but the brain stops registering it as a reward the way it once did.
That mechanism is the foundation of something called the Sinclair Method: you take naltrexone roughly one hour before drinking, then drink as you normally would. Over time, usually weeks to months, the brain’s conditioned response to alcohol gradually extinguishes. You’re not white-knuckling abstinence. You’re rewiring the association between drinking and reward.
Naltrexone comes in two forms: a daily 50mg pill, or a monthly injectable called Vivitrol. Both are effective; the injection can be useful for people who don’t want the daily reminder. Side effects are generally mild, with some nausea in the first week or two being the most common complaint, and they tend to fade as the body adjusts.
Crucially, naltrexone is designed to work with moderation, not just abstinence. It’s one of the few medications where drinking while taking it is part of how it works. That makes it a natural fit for people who aren’t seeking total sobriety, just a healthier relationship with alcohol. Learn more about how naltrexone is used for alcohol moderation, including how Sunnyside Med prescribes it as part of a broader support plan.
How GLP-1 Drugs Like Ozempic Affect Alcohol Cravings
GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), tirzepatide, and liraglutide, were developed for type 2 diabetes and obesity. But researchers noticed something in patients taking them: a quieting of cravings that extended well beyond food. Alcohol, nicotine, even gambling. The reward system was being dampened more broadly.
GLP-1 receptors are found throughout the brain’s reward center, including regions that regulate dopamine release. When a GLP-1 drug activates those receptors, it appears to reduce the dopamine spike triggered by alcohol. The end result resembles what naltrexone produces, but through a completely different pathway. Naltrexone blocks the opioid receptor → the reward signal from alcohol weakens. A GLP-1 drug activates the GLP-1 receptor → the dopamine response to alcohol is quieted. Two separate locks on the same door.
The emerging research is genuinely promising. A large-scale analysis of over 125,000 patients found that people on semaglutide had significantly lower rates of alcohol use disorder diagnoses. A JAMA Psychiatry trial showed reduced drinking in heavy drinkers taking a GLP-1 medication. Clinical trials specifically for alcohol use disorder are underway.
GLP-1 drugs are not FDA-approved for alcohol use disorder. Any prescriber who writes that script for drinking is doing so off-label. Insurance won’t cover it for that purpose, which means costs of $1,000 or more per month out of pocket. Side effects include nausea, GI distress, and potential blood sugar complications that can interact unpredictably with alcohol. The long-term data for using these medications specifically for drinking simply doesn’t exist yet, not the way it does for naltrexone. That absence of data is a reason for measured assessment of the research, not wholesale dismissal of it.
Naltrexone vs. GLP-1 Medications: Side-by-Side Comparison
On FDA approval, the gap is wide. Naltrexone has held that designation for alcohol use disorder since 1994. GLP-1 drugs carry no such approval for AUD and are prescribed off-label for that purpose. The evidence base follows the same pattern: naltrexone is backed by decades of randomized controlled trials and real-world clinical use, while GLP-1 research for drinking, though promising, currently rests on observational studies and a handful of early trials.
The cost difference is equally stark. Generic naltrexone typically runs $20-50 per month, with Vivitrol injections higher but often covered by insurance when prescribed for alcohol use disorder. GLP-1 drugs can exceed $1,000 per month for this use, since insurance does not cover them for that indication. Mechanistically, the two drugs differ at the receptor level but converge downstream: naltrexone blocks opioid receptors → alcohol’s rewarding effects diminish; GLP-1 drugs activate GLP-1 receptors in the brain’s reward center → the dopamine response to alcohol is reduced.
Dosing formats vary as well. Naltrexone is taken as a daily pill or monthly injection. GLP-1 medications are typically weekly injections, though daily pill forms exist depending on the specific drug. For side effects, naltrexone tends to cause mild nausea in early weeks that resolves on its own. GLP-1 drugs carry a heavier GI burden for many patients, along with blood sugar considerations that matter when alcohol is in the mix.
Naltrexone has been studied and used specifically within moderation frameworks for decades. GLP-1 research suggests reduced cravings, but no published trials have examined it within alcohol moderation programs. Availability also differs: naltrexone can be prescribed by most physicians and through services like Sunnyside Med, while GLP-1 prescriptions for drinking depend on individual prescriber willingness and access to specialized care.
Which Alcohol Moderation Medication Is Right for You?
There’s no universal answer, but there are clear patterns worth knowing.
If your primary goal is drinking less, naltrexone is the stronger starting point. The evidence is there. The FDA approval is there. The cost is manageable. It was developed with alcohol use disorder in mind, not repurposed from another condition. The Sinclair Method in particular offers a moderation-forward approach that doesn’t require abstinence as a first step.
If you’re already on a GLP-1 drug for weight management or diabetes and you’ve noticed your drinking naturally decreasing, that effect is real, it’s biological, and it’s worth discussing openly with your prescribing doctor.
If cost and insurance are significant factors, naltrexone wins decisively. A GLP-1 prescription for drinking will almost certainly come entirely out of pocket.
If you’re curious about combination approaches, some researchers believe naltrexone and GLP-1 drugs could work together by targeting two different but overlapping pathways in the reward system. That research remains in early stages and is a conversation to have with a physician who specializes in this area.
If you’re not sure where you fall, take Sunnyside’s free assessment to get a clearer picture of your relationship with alcohol and what kind of support might fit best.
Why Medication Works Best Alongside Behavior Change
Whether you’re exploring naltrexone, a GLP-1 drug, or both, the research is consistent on one point: medication alone is rarely the whole answer. The brain changes medication can support need behavioral reinforcement to stick.
Naltrexone blunts the reward signal from alcohol → the dopamine feedback loop weakens → over time, drinking loses its pull. But the triggers that send you reaching for a drink, whether stress, social situations, habit loops, or emotions, aren’t erased by a pill. Learning to identify and work with your triggers is what turns a pharmacological shift into a lasting behavioral one.
Tracking matters too. Seeing your weekly drink count, noticing patterns, and registering reductions create feedback loops that reinforce what medication starts. These mindful drinking practices give the brain new data to work with rather than leaving old habits in place. Understanding how dopamine and the brain’s reward system function in drinking makes the process feel less opaque and more actionable. The stress angle deserves attention as well: alcohol and cortisol interact in ways many people don’t anticipate, and addressing stress directly removes one of the biggest drivers of heavy drinking.
That combination of medication access and behavioral structure is what Sunnyside Med is built around: naltrexone prescribed with clinical oversight, alongside the tracking and support tools that help the medication do its job across the weeks and months when the real rewiring happens.
References
Anton RF, et al. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. JAMA, 295(17):2003-2017.
Volpicelli JR, et al. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49(11):876-880.
Sinclair JD. (2001). Evidence about the use of naltrexone for different ways of using it in the treatment of alcoholism. Alcohol and Alcoholism, 36(1):2-10.
Hendershot CS, et al. (2024). Semaglutide and alcohol use disorder. JAMA Psychiatry. JAMA
Leggio L, et al. (2023). GLP-1 receptor agonists are promising but unproven treatments for AUD. Nature Medicine, 29:2993-2995.
NIAAA. Medications for Alcohol Use Disorder. Updated 2023. niaaa.nih.gov
